Currently, there are 155.12M common shares owned by the public and among those 125.75M shares have been available to trade.
The company’s stock has a 5-day price change of 2.30% and -11.00% over the past three months. HUMA shares are trading -47.13% year to date (YTD), with the 12-month market performance down to -63.52% lower. It has a 12-month low price of $1.15 and touched a high of $9.79 over the same period. HUMA has an average intraday trading volume of 4.81 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 9.94%, 46.66%, and -32.09% respectively.
Institutional ownership of Humacyte Inc (NASDAQ: HUMA) shares accounts for 39.88% of the company’s 155.12M shares outstanding.
It has a market capitalization of $414.16M and a beta (3y monthly) value of 2.00. The earnings-per-share (ttm) stands at -$0.69. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.58% over the week and 7.72% over the month.
Analysts forecast that Humacyte Inc (HUMA) will achieve an EPS of -0.18 for the current quarter, -0.16 for the next quarter and -0.07 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.2 while analysts give the company a high EPS estimate of -0.2. Comparatively, EPS for the current quarter was -0.48 a year ago. Earnings per share for the fiscal year are expected to increase by 80.49%, and -14.69% over the next financial year.
Looking at the support for the HUMA, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on May 14, 2025, with the firm’s price target at $4. H.C. Wainwright coverage for the Humacyte Inc (HUMA) stock in a research note released on December 20, 2024 offered a Buy rating with a price target of $15. H.C. Wainwright was of a view on December 11, 2023 that the stock is Buy, while Piper Sandler gave the stock Neutral rating on August 14, 2023, issuing a price target of $2.75- $3.50. Cantor Fitzgerald on their part issued Overweight rating on June 22, 2023.
